SV Health Investors (formerly Schroder Ventures Life Sciences), founded 1994, manages ~$3.7-4b AUM across 7 specialist healthcare funds. 30-year transatlantic track record (US/UK/EU). Team 79+ (23 Partners, 34 Venture Partners). Portfolio: 238+ companies; 17 IPOs, 97+ M&A exits (Amwell, Insulet, Incyte, EyeBio $3b Merck exit 2024). Offices: Boston HQ, London, San Francisco. Expertise: precision therapeutics, dementia discovery, medtech convergence.
Investment Focus
Investment Thesis
Multi-stage healthcare VC spanning biotech therapeutics (early-to-late), medical devices, diagnostics, healthcare services & digital health. Specific focus: dementia/neurodegenerative (DDF fund), precision medicine, cancer, ophthalmology. Check sizes £5-30m+ (Series A avg ~$22m, Series B ~$33m). US-dominant (85%) with 15% EU exposure. Value-add: operating partners from pharma/medtech, company creation (De novo platform). Avoid: incremental/me-too products; focus unmet clinical needs.
Interested in connecting?
Visit their website or reach out directly.